Intensive Weekly Chemotherapy for Elderly Gastric Cancer Patients, Using 5-Fluorouracil, Cisplatin, Epi-Doxorubicin, 6S-Leucovorin and Glutathione with the Support of G-CSF

Cascinu, Stefano; Catalano, Giuseppina

doi:10.1177/030089169508100107

Cited by 7 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the frequent use of CDDP, due to the variance of GSH dose, only five studies (19%) used the same combination and dose on the same cancer (30, 31, 33–35). All of them were single-arm studies demonstrating that adding GSH to CDDP-based chemotherapy could improve tumor response in gastric cancer patients (compared to historical controls) with some also showing a neuroprotective effect.…”

Section: Resultsmentioning

confidence: 99%

“…First, a community of interested researchers must come to consensus and focus efforts on one, or a small number of antioxidant and conventional cancer therapy combinations and specific clinical research questions. This has been accomplished to a limited degree with the combination of glutathione and cisplatin-based chemotherapy for treatment of gastric cancer (30, 31, 33–35). Initial efforts should focus on a rational approach to selection of the antioxidant and chemotherapy or radiotherapy partner.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review: Generating Evidence-Based Guidelines on the Concurrent Use of Dietary Antioxidants and Chemotherapy or Radiotherapy

Nakayama¹,

Alladin

Igbokwe

et al. 2011

Cancer Investigation

View full text Add to dashboard Cite

The risk–benefit ratio for concurrent use of dietary antioxidants with chemotherapy or radiation therapy is a controversial topic. In this review, the medical literature on concurrent antioxidant use with chemotherapy or radiotherapy was assessed and further steps for generating evidence-based guidelines are suggested. The clinical cancer research community should cooperate and focus new studies on the use of a specific combination of antioxidant and chemotherapy or radiotherapy, and determine optimal doses for a specific cancer setting. Mechanistic studies on the interaction between antioxidants and conventional cancer therapy could lead to novel biomarkers for assessing dose adequacy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Systematic Review: Generating Evidence-Based Guidelines on the Concurrent Use of Dietary Antioxidants and Chemotherapy or Radiotherapy

Nakayama¹,

Alladin

Igbokwe

et al. 2011

Cancer Investigation

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, six phase II studies have been published in international peer-reviewed journals between 1990 and 2002 (Wilke et al, 1990;Cascinu et al, 1994;Cascinu and Catalano, 1995;Di Bartolomeo et al, 1995;Hartung et al, 2000;Ikeda et al, 2002). In five of these trials, chemotherapy consisted of leucovorin-modulated 5-fluorouracil in combination with cisplatin, epi-doxorubicin, etoposide or mitomycin-C. A phase II study investigated the toxicity profile and the activity of single-agent doxifluridine (Ikeda et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer

et al. 2003

View full text Add to dashboard Cite

The incidence of gastric cancer (GC) increases significantly after the fifth decade and palliative chemotherapy is the ultimate treatment in the majority of patients. We investigated safety and efficacy of a weekly regimen with cisplatin, fluorouracil and leucovorin as firstline chemotherapy for elderly patients with advanced GC. Chemotherapy-naive patients older than 65 years were considered eligible for study entry. Frail elderly patients were identified and excluded according to the following criteria: age 485 years, dependence in one or more activities of daily living (activities of daily living and instrumental activities of daily living scales), three or more comorbid conditions, one or more geriatric syndromes. Chemotherapy consisted of 1-day per week administration of intravenous cisplatin 35 mg m À2 , 6S-stereoisomer leucovorin 250 mg m À2 and fluorouracil 500 mg m À2 (PLF). Patients were re-evaluated after eight weekly cycles and six additional weekly administrations were planned for patients without disease progression. A 5-day subcutaneous filgrastim (5 mg Kg À1 day À1 , days þ 1-þ 5) was used after the first treatment delay for neutropenia and maintained thereafter. In the whole group, the best intention-to-treat overall response rate was 43% (95% CI: 30 -56%). The time to disease progression and the median survival time were 5.3 and 8.6 months, respectively. Fatigue was the commonest nonhaematologic toxicity (71% of the patients). Filgrastim was used in 30 patients who showed grade II (20 patients) or grade III (10 patients) neutropenia. Neither grade IV toxicity nor toxic deaths were observed. The weekly PLF regimen resulted safe and effective in elderly patients with advanced GC. This outpatient regimen is based on old and low-cost drugs and it may represent an alternative to new and more expensive combinations.

show abstract

Gastric cancer in the elderly

Kranenbarg

Velde

1998

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Intensive Weekly Chemotherapy for Elderly Gastric Cancer Patients, Using 5-Fluorouracil, Cisplatin, Epi-Doxorubicin, 6S-Leucovorin and Glutathione with the Support of G-CSF

Abstract: This regimen appears feasible also in elderly gastric cancer patients and, because of its activity, suitable for further studies.

Cited by 7 publications

References 8 publications

Systematic Review: Generating Evidence-Based Guidelines on the Concurrent Use of Dietary Antioxidants and Chemotherapy or Radiotherapy

Systematic Review: Generating Evidence-Based Guidelines on the Concurrent Use of Dietary Antioxidants and Chemotherapy or Radiotherapy

A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer

Gastric cancer in the elderly

Contact Info

Product

Resources

About